0401.HK falls 19.66% to HK$0.094 on 02 Jan 2026: key risk signals for investors
Wanjia Group Holdings Limited (0401.HK) fell 19.66% to HK$0.094 at market close on 02 Jan 2026, making it one of the top losers on the HKSE in Hong Kong today. The drop followed heavy intraday selling (volume 500,000 shares) after the stock opened at HK$0.101 and closed well below the 50-day average. This report on 0401.HK stock covers the price move, valuation, technical signals and an outlook tied to our forecast model and Meyka AI analysis.
Immediate market move and trading data
Wanjia Group Holdings Limited (0401.HK) closed at HK$0.094, down HK$0.023 or 19.66% on 02 Jan 2026. The session low was HK$0.093 and the session high was HK$0.102, with volume at 500,000 versus an average volume of 445,630. Market cap stood at HKD 56,022,214 with 560,222,136 shares outstanding. The stock opened at HK$0.101 and previous close was HK$0.117, indicating a sharp intraday reversal and elevated selling pressure.
Fundamentals and valuation snapshot
0401.HK shows trailing EPS of -0.02 and a negative P/E of -4.71, reflecting recent losses. Key valuation ratios: price-to-sales 0.23, price-to-book 0.83 and EV-to-sales 0.20. Revenue per share is HK$0.44 and book value per share is HK$0.12. Liquidity metrics remain reasonable with a current ratio of 1.96 and debt-to-equity of 0.16, suggesting a modest leverage profile despite negative profitability.
Technical indicators point to oversold conditions
Technicals show RSI at 33.42 and CCI at -123.27, signaling oversold momentum. The 50-day average price is HK$0.13 and the 200-day average is HK$0.10, placing the current price below the 50-day but near the 200-day average. ADX at 32.03 implies a strong trend, while Bollinger Bands (upper HK$0.15, middle HK$0.12, lower HK$0.09) show the stock trading toward the lower band. Traders should note Williams %R at -100.00, a short-term extreme.
Sector context and risk drivers
Wanjia operates in the Healthcare sector (Medical – Distribution) on the HKSE in Hong Kong. The healthcare sector’s average P/E is about 29.47 versus Wanjia’s negative P/E, highlighting a valuation gap. Sector momentum has outpaced this small-cap distributor, increasing relative risk for Wanjia if growth does not reaccelerate. Key risks include slower hospital procurement, margin pressure on distribution, and negative operating margins reported recently.
Meyka grade and analyst view
Meyka AI rates 0401.HK with a score out of 100: 62.67 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, and analyst consensus. The company reported negative EPS and last announced earnings on 25 Nov 2024, which influences the grade. These grades are informational only and not financial advice.
Near-term outlook and price targets
Short-term technicals favor careful monitoring rather than fresh buys. A reasonable near-term price target is HK$0.13 (monthly model) with a 12-month model target of HK$0.14, both derived from our forecast suite. If market sentiment improves and margins recover, resistance sits at the 50-day average near HK$0.13 and prior year high at HK$0.18. Monitor liquidity (volume) and quarterly results for confirmation.
Final Thoughts
Today’s 19.66% decline to HK$0.094 on 02 Jan 2026 made Wanjia Group Holdings Limited one of the HKSE’s top losers and exposed short-term downside risks tied to sentiment and profitability. Fundamentals show a low price-to-sales of 0.23 and price-to-book of 0.83, but negative EPS and weak margins keep earnings recovery uncertain. Technical indicators (RSI 33.42, CCI -123.27, ADX 32.03) point to oversold conditions but also a strong downtrend that needs volume-based confirmation to reverse. Meyka AI’s forecast model projects a 12-month price of HK$0.14, implying an upside of 52.30% versus the current price of HK$0.094; near-term model output is HK$0.13. Forecasts are model-based projections and not guarantees. Investors should weigh recovery signs in quarterly results and sector demand before adding exposure. This analysis uses data from HKSE (Hong Kong) and is produced by a Meyka AI-powered market analysis platform for informational purposes only.
FAQs
The 19.66% drop on 02 Jan 2026 followed heavy intraday selling, a move below the 50-day average and continued negative EPS pressure. Volume (500,000) exceeded recent averages and technical indicators showed oversold momentum.
Valuation metrics are low: price-to-sales 0.23 and price-to-book 0.83 suggest a discounted market value, but negative earnings (EPS -0.02) and margin weakness make the valuation risky until profitability improves.
Meyka AI’s near-term model points to HK$0.13 and the 12-month model to HK$0.14. These imply upside versus HK$0.094 but are model projections and not guarantees.
Given the negative EPS, weak margins and a strong downtrend, a HOLD stance is reasonable until the company reports improved earnings or volume confirms a trend reversal. Assess risk tolerance and time horizon.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
